Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma

NCT03710915 is registered in ClinicalTrials.gov with HitGen Inc. as lead sponsor.

NCT NCT03710915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03710915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma
Lead sponsor
HitGen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 12, 2019
Completion date
June 28, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, relapsed and refractory multiple myeloma